Partners
Ultivue by Vizgen and its partners are committed to bringing state-of-the-art integrated platform capabilities by combining pathology-grade spatial proteomics solutions with industry-leading clinically accepted operational standards.
By collaborating with clinical research industry leaders, Ultivue by Vizgen aims to empower pathologists, clinicians and researchers with robust high-throughput biomarker strategies to evaluate specific biological hypotheses with high precision.
Leica Biosystems is a cancer diagnostics company and a global leader in anatomic and digital pathology solutions. The company offers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. As the only company to own the full workflow from biopsy to diagnosis, Leica Biosystems is uniquely positioned to break down the barriers between each step. The company’s mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of its corporate culture. Leica Biosystems is proud to be a Danaher Corporation subsidiary.
ZEISS Microscopy empowers Biotech and Pharma industries with innovative imaging and workflow solutions for Tissue Multiplexing, 3D Human Tissue Models, and advanced Regulatory and Compliance workflow integration. Leveraging over 175 years of excellence in the fields of optics and optoelectronics, ZEISS combines cutting-edge microscopy solutions with expert Professional Services to enable accelerated discoveries, reproducible results, and regulatory readiness, helping you advance therapies and improve patient outcomes with confidence.
With over 46,000 employees, ZEISS is active globally in around 50 countries with more than 60 sales and service locations, around 40 research and development facilities, and 35 production facilities worldwide (30 September 2024). Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. The Carl Zeiss Foundation, one of the largest foundations in Germany committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG
Hamamatsu Corporation, the North American subsidiary of Hamamatsu Photonics K.K. in Japan, a world leader in the development and production of photonics devices, is proud to introduce MoxiePlex—a multiplex fluorescent tissue imaging platform. Designed to streamline and simplify spatial proteomics workflows, MoxiePlex provides low-plex fluorescent image data to deliver high-value information and bridges the gap between research and clinical applications. Evolved from our extensive experience providing medical imaging detectors, life science fluorescent imaging cameras, and digital pathology imaging systems, MoxiePlex is the next generation of Hamamatsu technology to enable scientific discovery. The launch of the MoxiePlex platform demonstrates Hamamatsu’s ongoing commitment to using light for the betterment of society, particularly in health and biology.
Lanterne Dx (LDX) is a full-service histopathology CRO offering discovery, translational, and clinical biomarker services. As a CAP-CLIA accredited provider, LDX specializes in biomarker development, including antibody development, optimization, and validation. Key capabilities include immunohistochemistry (IHC), immunofluorescence (IF), multiplexing, in situ hybridization (ISH), fluorescence in situ hybridization (FISH), and a wide range of microscopic applications. These services are complemented by both qualitative and quantitative pathology evaluations, advanced image analysis, and comprehensive data analysis—all designed to streamline and accelerate drug development efforts.
At Lanterne Dx, we are dedicated to being your trusted partner throughout the drug development journey, offering expert guidance from preclinical research to translational studies and into clinical applications.
HistologiX is a leading GLP/GCP compliant CRO supporting tissue-based evaluation of your biomarkers. Working collaboratively, their experienced scientific team provides bespoke, specialist histology, immunohistochemistry (IHC) including multiplex immunofluorescence (IF), multiplex in situ hybridization (ISH) using RNAScope, digital pathology, and image analysis services. They provide an excellent quality technical service supporting biomarker evaluation of cutting-edge therapeutics including cell and gene therapies, oncolytic viruses,
therapeutic antibodies, small molecules, and RNA-modifying enzymes.
HistoWiz is revolutionizing the field of histopathology by providing automated, high-quality histology and digital pathology services with industry-leading turnaround times. Utilizing state-of-the-art automation and their proprietary cloud-based platform, PathologyMap™, HistoWiz empowers researchers to quickly process tissue samples, digitize slides for instant viewing and management, and collaborate seamlessly. With a focus on speed, precision, and GLP compliance, HistoWiz accelerates scientific discovery and drug development, allowing our partners to focus on groundbreaking research.
Arkana Laboratories is the largest renal pathology practice in the United States, currently serving more than 3,000 nephrologists in 46 states and the District of Columbia and processing nearly 30,000 renal biopsies per year, representing approximately 35-40% of all medical kidney biopsies performed in the United States. Arkana has processed over 260,000 renal biopsies since its start of business in 2001. This gives us the unique opportunity to study samples from patients with a wide range of diseases. The Arkana biorepository collects samples from consented patients with kidney disease for research analysis. Arkana also offers neuropathology, molecular and serologic testing services, and we have a long history of reporting new disease entities and developing new diagnostic assays. Arkana is a fully compliant HIPAA ‘Covered Entity’ with CLIA accreditation, and the highest rating given by the College of American Pathology in our most recent laboratory inspection.
